Podcast
The Uromigos
Hosted by The Uromigos · EN
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
492episodes
Episodes
Newest firstAll episodes
Episode 484: ASCO GU 2026 - LITESPARK 022: Adjuvant Pembro + Belzutifan in RCC
Feb 2800:36:53Tap to summarizeThis in-depth discussion explores the latest advancements in adjuvant kidney cancer treatment, focusing on the recent phase 3 trial results of belzutifan combined with Pembrolizumab (LITESPARK-022), mechanistic insights, biomarker development, and future research directions.
Transcribe →Episode 482: ASCO GU 2026 - SUNRISE 2
Feb 2800:33:23Tap to summarizeThe conversation revolves around the Sunrise 2 trial, a study investigating the efficacy of TAR-200 combined with cetrilimab versus traditional chemoradiotherapy in muscle-invasive bladder cancer. The discussion covers the study's design, patient population, results, and implications for future treatment strategies, emphasizing the importance of patient selection and the potential for TAR-200 in earlier treatment settings.
Transcribe →Episode 483: ASCO GU 2026 - KEYNOTE B15: Neoadjuvant EVP vs Gem/Cis in Cis-eligible MIBC
Feb 2700:42:18Tap to summarizeIn this podcast , Brian, Tom and Matt Galsky discuss the B15 study data on neoadjuvant therapy for muscle invasive bladder cancer, focusing on the efficacy of EV Pembro compared to gem-cis. They explore event-free survival, overall survival, and the implications of treatment duration and individualization. The conversation also touches on the role of ctDNA in treatment decisions, alternative histologies, and the importance of neoadjuvant systemic therapy. The hosts conclude with reflections on future directions in bladder cancer treatment and the significance of ongoing studies.
Transcribe →Episode 480: ASCO GU 2026 - PEACE-3 and BRCAway Final OS Results
Feb 2600:43:08Tap to summarizeIn this episode, Evan Yu discusses the latest prostate cancer data presented at ASCO GU, focusing on the final overall survival results of the PEACE 3 trial, the implications of crossing survival curves, and the evolving role of radioligand therapy and PARP inhibitors in prostate cancer treatment.
Transcribe →Episode 479: Does the Timing of IO Infusion Impact Clinical Outcomes? A Critical Analysis
Feb 2300:39:47Tap to summarizeThis episode critically examines a recent Nature Medicine paper on the timing of immune therapy infusion in lung cancer, exploring the scientific plausibility, methodological concerns, and implications for future research. Tom, Brian and David McDermott debate the validity of the findings, the review process, and the need for rigorous prospective trials.
Transcribe →Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria
Feb 1600:45:59Tap to summarizeSummaryThis Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative process of developing guidelines that reflect the latest scientific evidence and clinical practices. The speakers discuss the new PCWG4 including new nomenclature, the role of imaging technologies like PSMA PET, and the importance of biomarkers and patient-reported outcomes in enhancing patient care and treatment efficacy. They emphasize the collaborative nature of the working groups and the ongoing need for adaptation in response to emerging data and technologies.
Transcribe →Episode 477: Uromigos Japan - GU Oncology 2025を総括!
Feb 1100:38:37Tap to summarize3人で前立腺癌、腎癌、尿路上皮癌の2025をレビューしました。
Transcribe →Episode 476: ASCO GU 2026 Preview
Feb 900:48:49Tap to summarizeIn this podcast , the Uromigos discuss the upcoming ASCO GU conference. They delve into the latest research findings, including phase 3 trials, combination therapies, and the significance of biomarkers in treatment. The conversation highlights the importance of belzutifan in kidney cancer and explores the evolving landscape of prostate and bladder cancer treatments. The hosts also share their predictions and insights on how these developments may impact clinical practice.
Transcribe →Episode 442: The History of ARPI Development in Prostate Cancer
Nov 2400:51:12Tap to summarizeMichael Morris from MSKCC joins us for an in-depth review of ARPI development across the spectrum of prostate caner
Transcribe →Episode 466: #UromigosLive 2025 - Novel Therapy in mRCC
Nov 1000:53:03Tap to summarizeBrian and Tom tag team moderate this session which covers combination data, VEGF/PD1 bispecifics, microbiome approaches, cellular therapy and enrichment strategies.
Transcribe →